title: Controversies in osteoporosis management: antiresorptive therapy for preventing bone loss: when to use one or two antiresorptive agents?
abstract: Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.
authors.affiliation: Departments of *Endocrinology; †Internal Medicine, Creighton University School of Medicine, Omaha, Nebraska.
authors.forename: J Christopher
authors.initials: JC
authors.lastname: Gallagher
authors.forename: Sri Harsha
authors.initials: SH
authors.lastname: Tella
mesh_terms: D019386:Alendronate / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002117:Calcitriol / Q000627:therapeutic use; D002136:Calcium, Dietary / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use
chemical_list: D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D004164:Diphosphonates; D020849:Raloxifene Hydrochloride; D002117:Calcitriol; D019386:Alendronate
references.citation: J Clin Endocrinol Metab. 2000 Feb;85(2):720-6
references.pmid: 10690882
references.citation: J Bone Miner Res. 2010 Oct;25(10):2256-65
references.pmid: 20533525
references.citation: JAMA. 2002 Jul 17;288(3):321-33
references.pmid: 12117397
references.citation: Int J Tissue React. 1999;21(2):51-9
references.pmid: 10568224
references.citation: Ann Rheum Dis. 1998 Jun;57(6):346-9
references.pmid: 9771208
references.citation: J Clin Endocrinol Metab. 2001 May;86(5):1890-7
references.pmid: 11344179
references.citation: Osteoporos Int. 2005 Apr;16(4):372-9
references.pmid: 15654581
references.citation: JAMA. 2003 May 21;289(19):2525-33
references.pmid: 12759324
references.citation: J Bone Miner Res. 1987 Dec;2(6):491-6
references.pmid: 3455633
references.citation: N Engl J Med. 1998 Feb 19;338(8):485-92
references.pmid: 9443925
references.citation: Fertil Steril. 2009 Sep;92(3):1045-1052
references.pmid: 19635616
references.citation: Arch Intern Med. 2004 Apr 26;164(8):871-9
references.pmid: 15111373
references.citation: J Clin Endocrinol Metab. 2002 Mar;87(3):985-92
references.pmid: 11889149
references.citation: Am J Med. 1998 Mar;104(3):219-26
references.pmid: 9552083
references.citation: Am J Clin Nutr. 1998 Jan;67(1):18-24
references.pmid: 9440370
references.citation: J Clin Endocrinol Metab. 1999 Sep;84(9):3076-81
references.pmid: 10487668
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28
references.pmid: 11502787
references.citation: Metabolism. 2006 Jun;55(6):741-7
references.pmid: 16713432
references.citation: JAMA. 1996 Nov 6;276(17):1397-403
references.pmid: 8892714
references.citation: JAMA. 2002 May 22-29;287(20):2668-76
references.pmid: 12020302